GT Biopharma Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de GT Biopharma.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como GT Biopharma no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:GTBP - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	N/A	-11	-12	-12	N/A
3/31/2024	N/A	-10	-10	-10	N/A
12/31/2023	N/A	-8	-9	-9	N/A
9/30/2023	N/A	-10	-11	-11	N/A
6/30/2023	N/A	-15	-12	-12	N/A
3/31/2023	N/A	-16	-13	-13	N/A
12/31/2022	N/A	-21	-15	-15	N/A
9/30/2022	N/A	-33	-15	-15	N/A
6/30/2022	N/A	-32	-16	-16	N/A
3/31/2022	N/A	-34	-17	-17	N/A
12/31/2021	N/A	-58	-16	-16	N/A
9/30/2021	N/A	-46	-14	-14	N/A
6/30/2021	N/A	-44	-12	-12	N/A
3/31/2021	N/A	-56	-11	-11	N/A
12/31/2020	N/A	-28	-7	-7	N/A
9/30/2020	N/A	-23	-6	-6	N/A
6/30/2020	N/A	-50	-5	-5	N/A
3/31/2020	N/A	-36	-3	-3	N/A
12/31/2019	N/A	-39	-4	-4	N/A
9/30/2019	N/A	-41	-4	-4	N/A
6/30/2019	N/A	-247	-7	-7	N/A
3/31/2019	N/A	-254	-7	-7	N/A
12/31/2018	N/A	-259	-11	-11	N/A
9/30/2018	N/A	-261	-12	-12	N/A
6/30/2018	N/A	-156	-10	-10	N/A
3/31/2018	N/A	-149	N/A	-9	N/A
12/31/2017	N/A	-144	N/A	-5	N/A
9/30/2017	N/A	-141	N/A	-3	N/A
6/30/2017	N/A	-14	N/A	-2	N/A
3/31/2017	N/A	-10	N/A	-2	N/A
12/31/2016	N/A	10	N/A	-2	N/A
9/30/2016	N/A	-14	N/A	-3	N/A
6/30/2016	N/A	-12	N/A	-3	N/A
3/31/2016	0	14	N/A	-3	N/A
12/31/2015	0	-21	N/A	-5	N/A
9/30/2015	0	-14	N/A	-5	N/A
6/30/2015	0	-17	N/A	-5	N/A
3/31/2015	0	-44	N/A	-3	N/A
12/31/2014	0	-23	N/A	-2	N/A
9/30/2014	0	-5	N/A	-1	N/A
6/30/2014	0	-1	N/A	0	N/A
3/31/2014	0	-1	N/A	0	N/A
12/31/2013	0	-1	N/A	0	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de GTBP es superior a la tasa de ahorro (2.5%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de GTBP crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de GTBP crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de GTBP crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de GTBP crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de GTBP se prevé que sea elevada dentro de 3 años.

GT Biopharma Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$4.00

Price target decreased to US$17.33

Price target decreased to US$17.33

Price target increased to US$25.33

Price target increased to US$25.33

Recent updates

GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Announces CFO Changes

New major risk - Shareholder dilution

GT Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $3.219 million.

New major risk - Financial position

GT Biopharma, Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Share price stability

GT Biopharma Announces 1 for 30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nasdaq Listing Qualifications Department Determines the GT Biopharma's Eligibility for an Additional 180 Calendar Day Period, or Until February 20, 2024, to Regain Compliance

New major risk - Revenue and earnings growth

New major risk - Market cap size

GT Biopharma, Inc. Announces Board Changes

We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate

Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee

Price target decreased to US$4.00

High number of new and inexperienced directors

GT Biopharma files for $150M mixed shelf offering

We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully

Gt Biopharma, Inc. Affirms Manufacturing Timeline for Lead Investigational Asset GTB-3650

GT Biopharma GAAP EPS of -$0.10 beats by $0.07

GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Index

GT Biopharma, Inc. Appoints Alan L. Urban to Fill Vacant Seat on Board

Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation

GT Biopharma, Inc., Annual General Meeting, Jun 08, 2022

Price target decreased to US$17.33

High number of new and inexperienced directors

GT Biopharma, Inc. Announces CEO Changes

GT Biopharma, Inc Appoints Manu Ohri as Chief Financial Officer

Price target decreased to US$17.33

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021

Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth

Price target increased to US$25.33

High number of new and inexperienced directors

GT Biopharma Announces Updated Positive Safety Data from Phase 1 GTB-3550 Monotherapy Trike Trial an Investigational Immunotherapy for Refractory Cancers to Be Presented At ESMO Congress 2021

GT Biopharma, Inc. Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies

GT Biopharma, Inc. announced delayed 10-Q filing

GT Biopharma Provides Second Quarter 2021 Business Update

Price target increased to US$25.33

GT Biopharma Announces Interim GTB-3550 Trike Monotherapy Clinical Trial Results

Getting To Know GT Biopharma

GT Biopharma, Inc. Announces Update on the Commencement of the GTB-3550 Trike Monotherapy Phase 2 Clinical Trial and Solid Tumor Trike Product Candidates

GT Biopharma names Gregory Berk Chief Medical Officer

GT Biopharma, Inc. announced delayed annual 10-K filing

GT Biopharma, Inc. Updates Interim GTB-3550 Trike™ Clinical Trial Results

GT Biopharma, Inc. Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer

GT Biopharma, Inc. Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE, a Novel NK Cell Therapeutic Cancer Treatment

Gt Biopharma, Inc. Sign an Expanded GMP Manufacturing Agreement with Cytovance Biologics

GT Biopharma, Inc. has completed a Composite Units Offering in the amount of $23.65 million.

GT Biopharma, Inc. Announces Board Changes

GT Biopharma Announces Eighth Patient Begins Treatment of GTB-3550

GT Biopharma, Inc. Announces TriKE™ for the Treatment of Breast and GI Cancers

Gt Biopharma, Inc. and Cytovance Reaches Agreement for License Rights to Use Certain Bacterial and Mammalian Cell Lines and for GMP Manufacturing Services Performed to Date Regarding the Company's Trike™ Product Candidates

Dr. Greg Berk, M.D. Joins Board of Directors of GT Biopharma, Inc

GT Biopharma, Inc. Appoints Michael Handelman as Chief Financial Officer

GT Biopharma, Inc. Announces Advisory Board Appointments

GT Biopharma, Inc. announced that it has received $0.25 million in funding

GT Biopharma, Inc. announced that it has received $5.607 million in funding

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento